JPC-3210

JPC-3210 is a potent experimental antimalarial small molecule of the 2-aminomethylphenol class, developed as an erythrocytic schizonticide. It demonstrates strong in vitro activity against multidrug-resistant *Plasmodium falciparum* lines and low cytotoxicity in mammalian cells. In vivo, it shows high efficacy against murine malaria and favorable pharmacokinetics, including high oral bioavailability and a long plasma elimination half-life. Mechanistically, JPC-3210 inhibits the hemoglobin digestion pathway in *P. falciparum* by depleting hemoglobin-derived peptides and reducing levels of hemoglobin, heme, and hemozoin within infected red blood cells. It acts as an intermediate inhibitor of β–hematin polymerization (less potent than quinoline antimalarials like chloroquine), with additional effects on parasite protein translation regulators. Its rapid parasite-killing kinetics make it a promising candidate for further development as a long acting partner drug for malaria treatment or prevention[1][2][3][4][5][6].

Other names

4-tert-butyl-2-[(tert-butylamino)methyl]-6-[5-fluoro-6-(trifluoromethyl)pyridin-3-yl]phenol